Prostate Cancer Evaluation Using PSA Tests

Initial Testing Approach

The National Comprehensive Cancer Network recommends ordering a total PSA (tPSA) test as the initial screening test, and if the total PSA is in the 4-10 ng/mL range with a normal digital rectal exam, adding a free PSA to calculate the percent free PSA (free/total PSA ratio) to improve specificity and reduce unnecessary biopsies 1, 2
A single elevated PSA should never prompt immediate biopsy—always verify with a second value before proceeding, as recommended by the Annals of Oncology 3

The percent free PSA (%fPSA) is clinically indicated when total PSA is between 4-10 ng/mL (the "diagnostic gray zone") and digital rectal examination is normal, according to the National Comprehensive Cancer Network 1, 2
A 25% free PSA cutoff detects 95% of prostate cancers while avoiding 20% of unnecessary biopsies, as reported by the National Comprehensive Cancer Network 1, 2

Complexed PSA (cPSA) measures PSA bound to alpha-1-antichymotrypsin and is FDA-approved, but has not gained widespread clinical acceptance, according to the National Comprehensive Cancer Network 1, 2
PSA Density (PSAD) requires transrectal ultrasound to measure prostate volume and is calculated as PSA value (ng/mL) divided by prostate volume (cc), as described by the National Comprehensive Cancer Network 1, 2

Recent urinary catheterization (especially traumatic) and benign prostatic hyperplasia can falsely elevate PSA, as noted by the Mayo Clinic Proceedings 4
5α-reductase inhibitors (finasteride, dutasteride) decrease PSA by approximately 50% in 6-12 months, and it is recommended to multiply the PSA by 2.3 for men taking these medications to determine true PSA value, according to the Mayo Clinic Proceedings 4

A PSA level of 0-2 ng/mL corresponds to a 1% probability of prostate cancer, as reported by the Annals of Oncology 5
A PSA level of >10 ng/mL corresponds to a >50-67% probability of cancer, according to the Annals of Oncology 5

If PSA is 4-10 ng/mL with normal DRE, add percent free PSA, as recommended by the National Comprehensive Cancer Network 1, 2
Verify abnormal results with repeat testing before proceeding to biopsy, as recommended by the Annals of Oncology 3

The American Urological Association no longer recommends a single threshold value of PSA to prompt prostate biopsy, and instead, the decision to proceed with prostate biopsy should be based on multiple factors including patient age, family history, ethnicity, prior biopsy history, and comorbidities 6, 7
PSA testing remains the best single test for early prostate cancer detection, though it should be combined with digital rectal examination (DRE) for optimal screening 8

The AUA recommends obtaining a baseline PSA at age 40 for men with an anticipated lifespan of 10 or more years 6, 7
Age-specific reference ranges for PSA should be considered when interpreting results, such as 0-3.5 ng/ml for White men aged 50-59 years 9

It is essential to use the same PSA assay for longitudinal monitoring as PSA assays are not interchangeable 10
Laboratory variability can range from 20-25% depending on standardization method, and assays using the 1999 World Health Organization standard yield results 20-25% lower than those using the Hybritech standard 10
For accurate PSA velocity measurement, at least three PSA values over a time period of at least 18 months are recommended 9

Several factors can affect PSA levels and should be considered when interpreting results, such as prostatitis, BPH, urethral/prostatic trauma, finasteride, and dutasteride, which can lower PSA by approximately 50% 10
Overdetection and overtreatment remain significant concerns with PSA screening, and men should be informed of the risks and benefits of prostate cancer screening before biopsy 6, 7
Active surveillance should be discussed as an option for certain men diagnosed with prostate cancer 11, 12